First, this study was mainly based on public databases for bioinformatics analysis and functional validation at the cellular level, and protein level expression validation of key molecules such as EPHB1, GSK3B, and p-SMAD3 has not yet been performed by clinical PRAD tissue samples, which lacks direct evidence support at the clinical sample level. The gene discussed is SMAD3; the disease is prostate adenocarcinoma.